Unknown

Dataset Information

0

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.


ABSTRACT: Introduction:Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic hrqol tool, the electronic Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemotherapy. Methods:Patients with advanced nsclc starting first-line chemotherapy were randomized to their oncologist receiving or not receiving their elcss-ql data before each clinic visit. Patients completed the elcss-ql at baseline, before each chemotherapy cycle, and at subsequent follow-up visits until disease progression. Prospective data about the pc referral rate, hrqol, and use of other supportive interventions were collected. Results:For the 95 patients with advanced nsclc who participated, oncologists received real-time elcss-ql data for 44 (elcss-ql arm) and standard clinical assessment alone for 51 (standard arm). The primary endpoint, the pc referral rate, was numerically higher, but statistically similar, for patients in the elcss-ql and standard arms. The hrqol scores over time were not significantly different between the two study arms. Conclusions:The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer.

SUBMITTER: Kuo JC 

PROVIDER: S-EPMC7253732 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Kuo J C JC   Graham D M DM   Salvarrey A A   Kassam F F   Le L W LW   Shepherd F A FA   Burkes R R   Hollen P J PJ   Gralla R J RJ   Leighl N B NB  

Current oncology (Toronto, Ont.) 20200401 2


<h4>Introduction</h4>Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic hrqol tool, the electronic Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemothe  ...[more]

Similar Datasets

| S-EPMC3241852 | biostudies-literature
| S-EPMC4917580 | biostudies-literature
| S-EPMC4226951 | biostudies-literature
| S-EPMC5889924 | biostudies-literature
| S-EPMC4466160 | biostudies-literature
| S-EPMC6445911 | biostudies-literature
| S-EPMC6699450 | biostudies-literature
| S-EPMC5802707 | biostudies-literature
| S-EPMC10501279 | biostudies-literature
| S-EPMC3083923 | biostudies-literature